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Abstract 
 
CAMOS (Cerebellar Ataxia with Mental retardation, Optic atrophy and Skin abnormalities) is a rare 
autosomal recessive syndrome characterized by a non-progressive congenital Cerebellar ataxia 
associated with Mental retardation, Optic atrophy and Skin abnormalities. Using homozygosity mapping 
in a large inbred Lebanese Druze family, we previously reported the mapping of the disease gene at 
chromosome 15q24-q26 to a 3.6cM interval between markers D15S206 and D15S199. Screening of 
candidate genes lying in this region led to the identification of a homozygous p.Gly1046Arg missense 
mutation in ZNF592, in all five affected individuals of the family. ZNF592 encodes a 1267-aa zinc finger 
protein, and the mutation, located within the eleventh zinc finger, is predicted to affect ZNF592‘s DNA 
binding properties. Although the precise role of ZNF592 remains to be determined, our results suggest 
that ZNF592 is implicated in a complex developmental pathway, and that the mutation is likely to 
disturb the highly orchestrated regulation of genes during cerebellar development, by either disrupting 
interactions with target DNA or with a partner protein. 
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Introduction 
Non Progressive Congenital ataxias (NPCA) are a small group of disorders, accounting for about 
10% of non-progressive infantile encephalopathies 1. Clinically, NPCA manifests in infancy with 
abnormal motor development, hypotonia, and delayed ability to sit and stand, followed by the 
appearance of ataxia 1. Dysarthria, mental retardation, and spasticity are also often present 2. 
Pathologically, most of the congenital ataxias are characterized by hypoplasia or atrophy of 
parts of the cerebellum and brain stem 3. It has been estimated that 50% of cases of congenital 
ataxia and mental retardation are genetically determined, most being of autosomal recessive 
inheritance 4.  To date, about seventeen loci responsible for NPCA are known, of which fourteen 
are of autosomal recessive transmission. When excluding the nine loci responsible  for Joubert 
syndrome, five loci are assigned to autosomal recessive NPCA:  Cayman ataxia (MIM 601238) at 
chromosome 19p13.3 5, due to mutations in ATCAY  (MIM 608179)6, Cerebellar ataxia 3 (SCAR6) 
at chromosome 20q11-q13 (MIM 608029)7, disequilibrium syndrome at chromosome 9p24 
(MIM 224050)8, “Norman type” ataxia (SCAR2 or CLA1) at chromosome 9q34-9qter (MIM 
213200)9, and CAMOS (SCAR5) at chromosome 15q24-q2610.  
ZNF592 is a 1267-aa zinc finger protein, predicted to contain thirteen classical C2H2-type zinc 
finger domains. C2H2 Zinc fingers (ZnF) were first discovered in transcription factor IIIA from 
Xenopus laevis11 and constitute one of the most common DNA-binding motifs found in 
eukaryotes12. C2H2-ZnF proteins usually play a crucial role as transcriptional regulators by 
mediating interactions between DNAs and proteins 11 and perform various functions in cellular 
processes, such as transcription, translation, metabolism and signalling by binding to nucleic 
acids or proteins 13, 14. 
In this study, we report the identification of a missense mutation in ZNF592, encoding a novel, 
highly conserved, zinc finger transcription factor, as the pathogenic mutation causing CAMOS, a 
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rare NPCA syndrome, where Cerebellar Ataxia is associated with Mental Retardation, Optic 
Atrophy and Skin abnormalities15. 
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Material and Methods 
 
Patients 
 We previously published the localization of CAMOS to chromosome 15q24-q26 in a large 
consanguineous Lebanese family (Fig 1) 10. Briefly, all patients share the following clinical 
features: severely delayed developmental milestones, severe psychomotor retardation, 
proportionate short stature, cerebellar spastic ataxia, microcephaly, optic atrophy, speech 
defect, ultrastructural skin abnormalities, and cerebellar atrophy, most probably of prenatal 
onset. For a fully detailed clinical description of the patients, see the work of Mégarbané et al.15. 
After informed consent was obtained from all individuals and parents of children included in this 
study, EDTA blood samples were collected and genomic DNA was extracted from lymphocytes 
using standard methods. All together, fifteen DNA samples were collected for the study, 
including 5 affected individuals (Fig1). All protocols performed in this study complied with the 
ethic guidelines of the institutions involved.  
 
Mutation analysis 
Of the twenty-four candidate genes present in the 3.6 cM homozygous interval, as described in 
the databases (Ensembl Genome Browser, UCSC Human Genome Browser), the following ten 
were selected, based on their function and tissue-specific expression; and tested for the 
presence of a pathogenic mutation: AP3B2, SH3GL3, BTBD1, HMG20A, HOMER2, RKHD3, 
EFTUD1, ZSCAN2, SCAND2 and ZNF592 (Fig 2A). Exploration of the entire coding sequence, as 
well as of exon-intron boundaries and 5’ and 3’ untranslated regions (UTRs), was performed for 
each candidate gene (Fig 2A). Intronic primers were designed using the Primer3 and OLIGOS 
v.9.3 softwares.  Primer sequences and annealing temperatures used for PCRs are available as 
supplementary material (Table 1). DNA sequences were obtained from the UCSC Human 
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Genome Browser (UCSC, March 2006 freeze), by comparing genomic DNA with cDNA sequences. 
Genomic DNA from Patient VI.14 and a control were amplified under standard PCR conditions. 
All PCR amplified fragments were analyzed by dHPLC/WAVE (Transgenomic, Omaha, NE, USA) 
and fluorescently sequenced in both directions, using an ABI 310 or ABI 3130 automated 
sequencer (Applied Biosystems, Foster City, USA), for those presenting abnormal elution profiles 
(conditions for dHPLC analysis are available upon request). Chromatograms were compared to 
reference sequences using Sequencher v4.2 (Gene Codes Corporation, Michigan, USA) and 
ChromasPro v1.33 (Technelysium, Tewantin, Australy).  
Segregation in the pedigree, of the identified c.3136G>A nucleotide change, as well as its 
presence in 444 Lebanese control chromosomes, were assessed by PstI restriction endonuclease 
digestion (Boehringner Mannheim) or dHPLC.  
 
Transcriptional analysis 
Total RNA was extracted from freshly isolated lymphocytes or immortalized lymphocytes, using 
standard protocols as described before 16. cDNAs were obtained from total RNA with use of 
Superscript I Reverse Transcriptase (Invitrogen Life Technologies) and random primers 
(InvitrogenLife Technologies), in accordance with the recommendations of the supplier. cDNAs 
were then PCR amplified as described above. Primers and annealing temperatures for 
amplification of the whole ZNF592 cDNA are available as supplementary material (Table 1). 
Primers corresponding to fragment 6 have been used for verification of the effect of the 
variation on ZNF592’s splicing.  
 
Semi-quantitative RT-PCR  
In human adult tissues, ZNF592’s expression profile was characterized, using Rapid Scan Gene 
Expression Panels from ORIGENE (Rockville, USA). These panels consist of cDNAs synthesized 
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from poly(A+) RNA and immobilized at four cDNAs concentrations (100X and 1000X) on a 96-
well PCR plate. Human panels include 24 different human adult tissues and 12 brain tissues 
(Supp. fig.1A-B). Expression of ZNF592 during development was assessed in 6 human foetal 
tissues by semi-quantitative RT-PCR using Multiple Choice cDNAs from ORIGENE (Rockville, 
USA), and, in mouse, using mRNAs extracted from whole embryo, at different developmental 
stages (Supp. fig.1D-E).  
Primers used for amplification are listed in Table 1 (Supplementary Material). In all experiments, 
ß-Actin was used for normalisation and amplified using primers included in the kit (ORIGENE, 
Rockville, USA).  
 
Northern-Blot 
Quantitative Northern-Blot analysis of ZNF592 expression in different human tissues was 
realized using commercially available synthetic polyA+ membranes from Ambion (Foster City, 
USA) and Clontech (Moutain View, USA), that were hybridized with a 972 bp radioactively 
labelled ([32P]-dATP) cDNA probe, covering ZNF592 exons 3 to 8. A Human ß-Actin cDNA probe 
provided by the manufacturer (ORIGENE, Rockville, USA) was used as a normalizing control. 
For patients’ Northern-Blot, we immobilized polyA+ mRNAs, extracted from homozygous patient 
VI.1 ’s, heterozygous father V.2’s and Lebanese control’s lymphoblastoid cells, using the µMacs 
mRNA isolation kit from Myltenyibiotech (Bergisch Gladbach, Germany); and the obtained 
synthetic membrane was hybridized to the 972 bp ZNF592  cDNA  probe cited above. All steps 
were realized using the NorthernMax-Gly kit (Ambion, Foster City, USA), following the 
manufacturer’s recommendations. 
 
Real-Time RT-PCR (QRT-PCR) 
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SYBR Green real-time PCRs (QRT-PCRs) were realized according to standard protocols in a 20-µl 
amplification mixture containing 10 μl of SYBR® Green PCR Master Mix buffer (Applied 
Biosystems, Foster City, CA, USA), 0.25 μM of each primer and 20 ng of RNAse H treated 
(Invitrogen Life Technologies) cDNAs obtained from reverse transcription of 5µg of DNAse I–
treated total RNA extracted from homozygous patient VI.1, heterozygous father V.2 and 
controls blood lymphocytes by use of the High Capacity cDNA Archive Kit (Applied Biosystems). 
Reactions were performed and data collected on the ABI PRISM 7500 Sequence Detection 
System (Applied Biosystems, Foster City, CA, USA) using conditions recommended by the 
manufacturer. Each assay included non-template controls and the unknown samples in 
triplicates: i.e patient VI.1, heterozygous father V.2. For ZNF592, five different calibrators 
(Lebanese controls) were used. All experiments have been repeated twice, with a freshly 
extracted mRNA from patient VI.1 and father V.2. The expression values of ZNF592 were 
normalized to that of GUS and GAPDH, while CCDN1 and CCDN2 expression values were 
normalized to that of TBP and GUS. For each gene, the expression ratio for a sample was 
calculated as the ratio between the average mRNA signal in the patient and the signal from 
calibrators. After the reaction, the data were analyzed using the comparative CT relative 
quantification method with ABI PRISM 7500 system SDS software version 1.2.3 (Applied 
Biosystems, Foster City, CA, USA). Primers for QRT-PCR were designed using Primer Express 
software version 2 (Applied Biosystems, FosterCity, CA, USA). All primer sequences are listed in 
Table 1 (Supplementary Material). Results are presented as average values for experiments with 
GUS as a normalizing gene. 
 
Protein homology modelling studies 
Wild-type and mutant eleventh ZNF592’s C2H2 Zinc Finger (ZnF) were modelized using freely 
available Swiss-Pdb Viewer software. As no PDB structure was available for ZNF592 in the 
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Protein Data Bank (PDB), we used the structure of the C2H2 zinc-binding domain from 
ZFP64/ZNF338 (PDB ID : 1X5W), another human zinc finger protein, presenting sequence 
homologies with ZNF592’s zinc fingers. Using Swiss-Pdb Viewer, we changed all amino acids (aa) 
to ZNF592 aa. In the mutant ZnF, the glycine at position 41 was replaced by an arginine, as 
observed in patients affected with CAMOS, who harbour the p.Gly1046Arg missense mutation. 
In the mutant C2H2 zinc-finger domain 3D structure (B), mutation of Gly41 to Arg41 results in 
the formation of a new hydrogen bond interaction between Arg41 and the adjacent tyrosine 
Tyr42. 
 
Web resources 
GenBank Accession numbers: 
AP3B2: NM_004644 
 SH3GL3: NM_003027 
 BTBD1: NM_025238 
 HMG20A: NM_018200 
 HOMER2: NM_199330 
 RKHD3: NM_032246 
 EFTUD1: NM_024580 
 ZSCAN2: NM_181877 
 SCAND2 : NM_033634 (the sequence was suppressed afterwards as the transcript is in fact a 
NMD transcript) 
ZNF592: BC094688, NM_014630, NC_000015, ENST00000299927,  ENSG00000166716 
In the databases, discrepancies exist between GenBank (NM_014630 and NC_000015), the UCSC 
Genome Browser, and the Ensembl browser (ENST00000299927,  ENSG00000166716) 
concerning the length of the transcript (but not the CDS), the number of exons, the length of the 
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UTRs and the region covered by ZNF592. Based on results of Northern blot experiments (see 
Suppl. Fig 1C), we used the sequence with Acc. Number BC094688, as a reference in our study. 
ZFP64/ZNF388: NP_060667 
PDB ID for ZFP64/ZNF338: 1X5W 
ZNF592  proteins: NP_055445 (Homo sapiens),  NP_848822 (Mus musculus),  XP_001084237 
(Macaca Mulatta), NP_001099742 (Rattus norvegicus), XP_545869 (Canis familiaris), 
XP_001916274 (Equus Caballus), NP_001095506 (Bos Taurus), XP_001364673 (Monodelphis 
domestica), NP_001072160 (Xenopus Tropicalis), NP_001038678 (Danio Rerio). 
 
URLs: 
Online Mendelian Inheritance in Man (OMIM): http://www.ncbi.nlm.nih.gov/Omim 
Design of primers available at http://frodo.wi.mit.edu/ 
The UCSC Genome Browser is available at http://genome.ucsc.edu/cgi-bin/hgGateway. 
Ensembl Server: http://www.ensembl.org/ 
NCBI dbSNP database: http://www.ncbi.nlm.nih.gov/SNP/ 
RCSB Protein Databank: http://www.rcsb.org/pdb/home/home.do 
Swiss-Pdb Viewer: http://spdbv.vital-it.ch/ 
DEPP (Disorder Enhanced Phosphorylation predictor): 
http://www.pondr.com/Phosphorylation_PONDR 
 
 11
 
Results  
Using DNA pooling and homozygosity mapping, we had previously assigned CAMOS to a 3.6 cM 
(5.7 Mb) homozygous region at chromosome 15q24-q26 between markers D15S206 and 
D15S199, in a large consanguineous Lebanese family, with five affected individuals 10 (Fig 1). 
Screening of the coding sequence of genes lying in the candidate interval, by direct sequencing, 
allowed us to identify a c.3136G>A homozygous transition in exon 6 of ZNF592, a gene encoding 
a 1267-aa zinc finger protein, and predicted to contain thirteen classical C2H2-type zinc finger 
domains (Fig 2). The c.3136G>A nucleotide change identified in our patients  was not reported in 
the NCBI dbSNP database, segregated perfectly with the phenotype in the pedigree and was not 
found in the 444 tested Lebanese control chromosomes, excluding the possibility that it might 
be a rare polymorphism and indicating that this variant was likely to be pathogenic. As the 
variation is affecting the second last nucleotide of exon 6, just upstream the 5’ consensus donor 
splice site, we tested whether it might affect splicing of ZNF592 transcript. RT-PCR studies using 
total RNAs extracted from patients and Lebanese control’s blood lymphocytes, and primers 
located in exons surrounding ZNF592 exon 6, allowed us to rule out this hypothesis, at least in 
the tested tissue (Fig 2C). Occurrence of small deletions/insertions was excluded by sequencing 
of the obtained RT-PCR fragment in patients and control. Other complex splicing defects were 
excluded by amplification and sequencing of the entire cDNA. At the protein level, the ZNF592 
c.3136G>A mutation is likely to be a missense mutation, leading to the replacement of a glycine 
by an arginine at residue 1046 (p.Gly1046Arg; GGG>AGG). It targets a highly conserved amino 
acid residue among eutherian mammals, located in the eleventh C2H2 zinc-finger domain, at the 
base of the loop between the two conserved cysteines (Fig 3).  
Protein homology modelling using wild-type and mutant predicted C2H2 zinc-finger domain 3D 
structure showed that mutation of glycine to arginine results in the formation of a new 
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hydrogen bond interaction between Arg41 and the adjacent tyrosine Tyr42 in the mutant C2H2 
zinc-finger (Fig 4).  
Considering the specificity of tissues involved in our pathology (CNS and skin), we characterized 
ZNF592’s expression profile, in both human and mouse tissues (Supp. fig. 1). Both semi-
quantitative RT-PCR experiments, using Rapid Scan Gene Expression Panels from ORIGENE 
(Rockville, USA), and Northern Blot experiments demonstrated ubiquitous expression of ZNF592 
in all studied human adult tissues, notably in brain and skin, with higher expression in skeletal 
muscle (Supp. fig 1A-C). In the Central Nervous System (CNS), ZNF592 is expressed widely, 
including in cerebellum and cerebellar vermis, with higher expression in Substantia Nigra (Supp. 
fig 1B). Very low levels of ZNF592 mRNA were detected in ovary, uterus and salivary glands 
(Supp. fig 1C). Finally, semi-quantitative RT-PCR experiments showed expression of ZNF592 in six 
tested human foetal tissues and early expression of Zfp592 (ZNF592 mouse ortholog) during 
development: as early as embryonic day E10 in whole mouse embryo (Supp. fig 1D-E). In mouse 
brain, Zfp592 mRNAs were detectable at birth (P0) and adult stages (Supp. fig 1E).  
In patients affected with CAMOS, we analysed ZNF592’s mRNA levels using Northern Blot and 
Quantitative Real-Time RT-PCR (QRT-PCR). Both experiments evidenced higher levels of ZNF592 
transcript levels in both the patient, and heterozygous father, as compared to control (data not 
shown for Northern Blot and Supplementary figure 2 for QRT-PCR), with a mean 3-fold increase 
in patient VI.1. Surprisingly, ZNF592 transcripts levels were even higher in the heterozygous 
father. No statistical analysis could be performed due to the small size of the sample (only one 
patient), however all experiments have been performed in triplicates and have been repeated 
twice, with freshly extracted total RNA samples in the second experiment. Unfortunately, we 
were not able to confirm these results at the protein level, as a polyclonal antibody against 
ZNF592 generated in rabbit failed to detect ZNF592 in control tissues (data not shown).  
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We studied the expression of cyclin-D1 (CCND1) and -D2 (CCND2) in CAMOS patient VI.1 ‘s 
lymphocytes using QRT-PCR. Interestingly, we found an increase in CCND1 and CCND2 mRNA 
levels; again, both in the patient and in the heterozygous father as compared to control, with a 
mean 43-fold and 3-fold increase in CCND1 and CCND2 patient’s transcripts levels respectively. 
As for ZNF592, no statistical analysis could be performed, but all experiments have been 
performed in triplicates and have been repeated twice. 
 
Discussion 
CAMO is a rare non progressive cerebellar ataxia syndrome, where Cerebellar Ataxia is 
associated with Mental Retardation, Optic Atrophy and Skin abnormalities15. Since the first 
report and localization of the gene at chromosome 15q24-q26 in a large consanguineous 
Lebanese family 10,15, no additional patients have been reported, pointing out the very low 
prevalence of this disease. In this study, we report the identification of a c.3136G>A missense 
mutation (p.Gly1046Arg) in ZNF592, in patients from this family. ZNF592 is a novel, highly 
conserved, 1267-aa zinc finger protein, predicted to contain thirteen classical C2H2-type zinc 
finger domains (ZnF) (Fig 2A and 3A), which constitute one of the most common DNA-binding 
motifs found in eukaryotes12. Several genes encoding zinc-finger proteins have been implicated 
in human pathologies, such as ZNF215 in Beckwith-Wiedemann syndrome17 (MIM 130650); 
ZNF41 (MIM 314995)18, ZNF8119 (MIM 314998) and ZNF67420 (MIM 300573) in non syndromic, 
X-linked mental retardation or ZNF750 in Seborrhea-like dermatitis with psoriasiform 
elements21. ZNF592 is the first gene of this family found to be mutated in a cerebellar syndrome, 
although mutations have been described in APTX (MIM 606350), the gene mutated in 
oculomotor-apraxia (AOA1) and encoding aprataxin, a nuclear protein with a role in DNA repair 
and containing one C2H2 ZnF22,23.  
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The p.Gly1046Arg mutation identified here targets a highly conserved amino acid and is located 
within the eleventh zinc finger of ZNF592. In silico protein homology modelling studies predict a 
destabilizing effect for the mutation, via the formation of a new hydrogen bond interaction 
between the mutated arginine and the adjacent Tyrosine (Fig 4), thereby leading to the 
disruption of the ZnF, as described for other transcription factors 24,25,26. By affecting ZNF592’s 
DNA binding properties or interactions with other TFs, the p.Gly1046Arg mutation in ZNF592 
might also regulate ZNF592’s own expression, as evidenced by the higher levels of ZNF592 
transcripts observed in the studied patient homozygous for the p.Gly1046Arg mutation. Thus, 
the ratio of wild-type versus mutant ZNF592 might be crucial, explaining the peculiar pattern of 
expression observed in heterozygote father versus homozygote patient. 
The multiplicity of tissues/organs involved, as well as the non-progressive nature of CAMOS, is 
characteristic of a developmental disease, with abnormal development of the cerebellum as a 
hallmark. Several genes for congenital human cerebellar malformations have been identified to 
date, including members of the Zic family of C2H2 zinc finger TFs27. Indeed, heterozygous 
deletions of the adjacent ZIC1 (MIM 600470) and ZIC4 (MIM 608948) genes cause Dandy-Walker 
malformation (MIM 220200), the most common human congenital cerebellar malformation27, 
and deletion of Zic1 in mouse results in cerebellar malformations and axial skeletal 
abnormalities28. Zic genes play critical roles in a variety of developmental processes and are 
regulated by a number of pathways/TFs. We postulate that ZNF592 might be a downstream or 
upstream element in the Zic regulated pathways. By disrupting the interactions between 
ZNF592 and its target consensus sequence, or between ZNF592 TF and another TF (as described 
for Zic with members of the Gli family of C2H2 TFs29,30), the p.Gly1046Arg mutation identified 
here is likely to affect the pathways regulated by Zic genes. This hypothesis is supported by the 
early expression of ZNF592, as early as E10 (Supp. fig 1E), the non progressive nature of CAMOS, 
and the presence of a dilated fourth ventricle in CAMOS patients as observed in patients 
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affected with Dandy-Walker malformation. Cyclin D1 (MIM 168461), a downstream effector of 
Zic proteins31 , shows reduced transcript expression levels in the cerebella of Zic mutants32, and 
mice lacking cyclin D1 and cyclin D2 (MIM 123833)  (cyclin D3-only mice) lacked normally 
developed cerebella33. In our patient’s lymphocytes, we observe an increase in cyclin-D1 
(CCND1) and -D2 (CCND2) mRNA levels, especially important for CCND1 (43 fold increase). 
Although preliminary, these results of altered expression patterns are extremely interesting and 
bring further support to the hypothesis of ZNF592, as a TF implicated in a complex 
developmental pathway. Indeed, D1-cyclin has been shown to be upregulated by Notch 
signalling34, known to inhibit differentiation of cerebellar granule neuron precursors by 
maintaining proliferation35. Abnormally elevated levels of cyclin D1 in cerebellar granule neuron 
precursors, by disrupting proliferation/differentiation processes in these cells, might have 
impaired cerebellar development in our patients.  In this context, the surprisingly elevated levels 
of ZNF592, cyclin D1 and D2 transcripts in the heterozygous father (Supp. fig. 2), are difficult to 
interpretate, but might be explained by the fact that the regulation of the described pathways is 
highly orchestrated in time, and that the amount of each TF might change rapidly in time, with a 
combination of tightly regulated levels of expression.  
In conclusion, this study describes the identification of ZNF592 as the gene responsible for 
CAMOS, a rare, non progressive, cerebellar ataxia syndrome previously identified in a Lebanese 
family. Further studies have to be performed in order to elucidate the pathophysiological 
mechanisms underlying CAMOS. However, our results allow us to formulate the hypothesis that 
ZNF592 might be implicated in a complex developmental pathway, affecting several tissues, 
such as the “Zic/Cyclin/Notch” pathway. A major argument in favour of the involvement of 
ZNF592 in this pathway is the presence, in our patients, of an inversion of the usual osmiophilic 
pattern of the vessels in skin biopsies:  the endothelial cells in patients are osmiophilic, 
compared to normal endothelium, which is electrolucent15. Indeed, neural and vascular 
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precursors use common signals and pathway, such as Notch, Sonic Hedgehog (Shh) or BMP, to 
specify their fate; and neural and vascular cells influence the cell- fate decision making of one 
another36. The Notch pathway, in particular, has a crucial role in arterial Endothelial Cell (EC) 
specification, by inducing arterial fate at the expense of venous EC fate36.  Implication of ZNF592 
in a pathway common to neural and vascular progenitors would explain the affection of both 
tissues in CAMOS.  
The identification of ZNF592 as the defective protein in CAMOS constitutes a first step in 
the comprehension of the pathophysiological mechanisms underlying this syndrome. Further 
experiments will be conducted in order to better define which pathways are involved.  
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Legends to figures and tables 
 
Figure 1. Pedigree of the Lebanese family 
Blackened symbols indicate the affected individuals. Gray circles indicate patients affected with 
diastrophic dysplasia, another autosomal recessive disease segregating in this pedigree. 
 
Figure 2. Candidate genes in the homozygous region identified in CAMOS with, identification 
of mutations in ZNF592. 
 (A) Chromosomal region at 15q24-q26 containing the CAMOS candidate locus as previously 
identified10, covering a 5.7 Mb (3.6 cM) region located between STR markers D15S206 
(AFM299yf9) and D15S199 (AFM107xg7). The 24 known genes lying in this region are 
schematically represented, with candidate genes tested in our study indicated in blue. ZNF592 is 
represented in red. ZNF592 is located at chromosome 15q25.3, covering a genomic region of 
about 20 kb, and is transcribed in direction centromere to telomere, as indicated by the black 
arrow.  In ZNF592 ‘s transcript, coding exons are represented in red and pink. ZNF592 is 
composed of 8 exons and the transcript is 4312 bp long (Acc. Number BC094688), with a coding 
sequence of 3804 bp (exons 1-8).In the protein ZNF592, the thirteen C2H2 Zinc Finger (ZnF) 
domains are represented by boxes. Location of the mutation identified in this study is indicated 
by an asterix in exon 6 of the gene, or in the eleventh zinc finger of the protein.  
 (B) Chromatograms showing the c.3136G>A mutation identified in ZNF592 exon 6 in the 
Lebanese patients. Lebanese control sequence is shown in a control. 
(C) Effect of the mutation on the trancription: agarose gel migration showing a transcript of 
normal size in the patients. Chromatograms showing the absence of small deletions/insertions 
and the c.3136G>A missense mutation giving rise to the replacement of a glycine by an arginine 
in the protein (p.Gly1046Arg). 
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Figure 3. Schematic representation of the zinc fingers (ZnF) and conservation between species 
(A) Schematic representation of ZnFs ten and eleven, showing the location of the mutated 
glycine at residue 1046, at the base of the 11th ZnF. (B) Multiple alignment between human 
ZNF592 protein and several orthologs. The glycine at residue 1046 mutated in our study is 
indicated in red and is highly conserved among eutherian mammals 
 
Figure 4. 3D structures of wild-type and mutant ZNF592 C2H2 Zinc finger  
Wild-type (A) and mutant (B) eleventh C2H2 Zinc Finger (ZnF) modeling using freely available 
Swiss-Pdb Viewer software. In the mutant C2H2 zinc-finger domain 3D structure (B), mutation of 
Gly41 to Arg41 results in the formation of a new hydrogen bond interaction between Arg41 and 
the adjacent tyrosine Tyr42. 
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Legends to supplementary tables and figures 
 
Supplementary Figure 1. Expression Analysis 
(A) Semi quantitative expression of ZNF592 in 24 different human adult tissues. 
cDNAs synthesized from poly(A+) RNA and immobilized at four cDNAs concentrations (1X, 10X, 
100X and 1000X) on a 96-well PCR plate, were amplified using  primers located in ZNF592 exons 
1 and 2 (see Supp. table 1). 
(B) Semi quantitative expression of ZNF592 in 12 different parts of the central nervous system, 
using immobilized cDNAs at two concentrations as in (A). ZNF592 is expressed widely, including 
in cerebellum and cerebellar vermis, with higher expression in Substantia Nigra. 
 (C) Quantitative Northern-Blot analysis of ZNF592 expression in different human tissues. 
(D) Expression of ZNF592 in human foetal tissues. NTC: non template control. 
(E) Expression of mouse Zfp592 at different developmental stages.  
Whole mouse embryo cDNAs at different embryonic days. E 10: embryonic day 10. E12: 
embryonic day 12. E15: embryonic day 15. E18: embryonic day 18. P0 brain: mouse brain at 
birth. Adult brain: mouse adult brain. NTC: non template control.  
 
Supplementary Figure 2. Quantitative Real time RT-PCR (QRT-PCR) 
 (A) Quantification of ZNF592 transcripts’ levels in patients affected with CAMOS by QRT-PCR. 
(B) Quantification of cyclin-D1 and -D2 transcripts levels in patients affected with CAMOS by 
QRT-PCR. 
Results are presented as average values, with GUS as the normalization gene. Het: father V.2. 
Hom: patient VI.1.  
 
Supplementary Table 1.  
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Primers sequences and annealing temperatures used for the analysis of ZNF592 coding 
sequence at the genomic and transcriptional level. Specific primers for real time RT-PCR are also 
mentioned. All human primers for genomic screening of mutations have been selected based on 
comparison of genomic DNA sequence with Genbank cDNA sequence BC094688.  
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